EMA Authorised: Raxone (idebenone) — Chiesi Farmaceutici S.p.A

View source ↗

Summary

The EMA authorised Raxone (idebenone) from Chiesi Farmaceutici S.p.A. for use in Leber hereditary optic neuropathy (hereditary optic atrophy).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• Raxone (idebenone)

Snippet

Status: Authorised. Therapeutic area: Optic Atrophy, Hereditary, Leber. MAH: Chiesi Farmaceutici S.p.A. Decision date: 19/08/2025